#SFHS2608599AApril 9, 2026 Order Modifying the List of Pharmaceutical Specialties Approved for Use by Public Entities and Various Public Services
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
This order adds specific pharmaceutical products used for treating chronic hypoparathyroidism to the list of medicines approved for public institutions in France. This means that these medicines will be covered by health insurance for those who need substitute PTH therapy and are not well-controlled by other treatments. Doctors experienced in this condition must start the treatment.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- Addition of specific pharmaceutical products for chronic hypoparathyroidism treatment to approved list
- Health insurance coverage for these pharmaceuticals in public entities
- Treatment initiation by experienced health professionals
Obligations
What this law requires
Publish this order in the Journal officiel de la République française (Official Journal of the French Republic)
Add the three YORVIPATH (palopegteriparatide) pharmaceutical formulations (168 mg/0.56 ml, 294 mg/0.98 ml, and 420 mg/1.4 ml injectable solutions) to the official list of medicines approved for use by public entities and public services
Cover YORVIPATH treatment through health insurance (assurance maladie) only for adult patients with chronic hypoparathyroidism requiring PTH substitution therapy who are not optimally controlled by vitamin-calcium treatment
Ensure that initiation and supervision of YORVIPATH treatment is performed only by physicians or healthcare professionals qualified and experienced in diagnosing and managing hypoparathyroidism patients
Verify that patients receiving YORVIPATH meet the specific therapeutic indication criteria (chronic hypoparathyroidism with need for PTH substitution therapy and suboptimal control by vitamin-calcium treatment) before authorizing reimbursement